Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665729 | 0.83 | TSHR (0.48) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL2608181 | 0.79 | TSHR (0.61) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL1755538 | 0.79 | TSHR (0.57) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL12259953 | 0.77 | TSHR (0.50) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL820628 | 0.77 | TSHR (0.50) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL3783039 | 0.77 | TSHR (0.58) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL3939041 | 0.77 | TSHR (0.58) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10337183 | 0.77 | TSHR (0.58) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL10308361 | 0.76 | ADRA2A (0.30) | — | |
| SCHEMBL2608176 | 0.76 | TSHR (0.69) | TSHRALDH1A1TP53HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570787-B2 | Curable compositions and articles prepared therefrom | TRANSITIONS OPTICAL, LTD. (IE) | 2026-03-10 | — | — | US | disclosed |
| EP-4562458-A1 | CURABLE PHOTOCHROMIC COMPOSITIONS INCLUDING HYDRAZIDE AND CARBONYL FUNCTIONAL COMPONENTS | Transitions Optical, Ltd. (IE) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024022586-A1 | CURABLE PHOTOCHROMIC COMPOSITIONS INCLUDING HYDRAZIDE AND CARBONYL FUNCTIONAL COMPONENTS | TRANSITIONS OPTICAL, LTD. (IE) | 2024-02-01 | — | — | WO | disclosed |
| US-20230323011-A1 | Curable Compositions and Articles Prepared Therefrom | TRANSITIONS OPTICAL, LTD. (IE) | 2023-10-12 | — | — | US | disclosed |
| EP-4204473-A1 | CURABLE COMPOSITIONS AND ARTICLES PREPARED THEREFROM | Transitions Optical, Ltd. (IE) | 2023-07-05 | — | — | EP | disclosed |
| CN-115968382-A | Curable compositions and articles prepared therefrom | 光学转变有限公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2022042841-A1 | CURABLE COMPOSITIONS AND ARTICLES PREPARED THEREFROM | TRANSITIONS OPTICAL, LTD. (IE) | 2022-03-03 | — | — | WO | disclosed |
| CN-110620185-A | Organic light emitting device | 三星显示有限公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570787-B2 | Curable compositions and articles prepared therefrom | EHMT2, EHMT1, BHMT2 | TSHR 3505/4885ALDH1A1 1039/4885TP53 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.